NCT04196205

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Study Evaluating the Safety and Efficacy With Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The First Affiliated Hospital of Nanchang University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm, open-label, single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients with relapsed or refractory acute lymphoblastic leukemia and Lymphomas.

Detailed description

CD19 has been extensively evaluated as a therapeutic target for relapsed or refractory B cell malignancy by chimeric antigen receptor T cell therapy,this is a single arm, open-label, single center study to determine the safety and efficacy of Anti-CD19 CAR-T cells in patients with refractory acute lymphoblastic leukemia and Lymphomas.

Conditions

• Acute Lymphoblastic Leukemia ,Lymphomas

Interventions

Type	Name	Description
BIOLOGICAL	Anti-CD19 CAR-T	1 - 2×10\^6 Anti-CD19 CAR-T cells/kg body weigh

Timeline

• Start date: 2019-12-01
• Primary completion: 2020-08-01
• Completion: 2021-08-01
• First posted: 2019-12-12
• Last updated: 2019-12-12

Locations

1 site across 1 country: China